Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines
June 2nd, 2018
9.9K views
This protocol describes the steps needed to design and perform multiplexed targeting of enhancers with the deactivating fusion protein SID4X-dCas9-KRAB, also known as enhancer interference (Enhancer-i). This protocol enables the identification of enhancers that regulate gene expression and facilitates the dissection of relationships between enhancers regulating a common target gene.
Overview
This protocol outlines the design and execution of multiplexed targeting of enhancers using the SID4X-dCas9-KRAB fusion protein, facilitating the identification of enhancers that regulate gene expression.
Key Study Components
Area of Science
- Genomics
- Gene Regulation
- Enhancer Targeting
Background
- Enhancers are crucial regulatory regions that control transcription.
- Understanding enhancer interactions is vital for elucidating gene expression mechanisms.
- This method allows simultaneous testing of multiple enhancers.
- Guide RNA design is a critical step in this protocol.
Purpose of Study
- To identify enhancers that regulate specific target genes.
- To dissect the relationships between enhancers and gene expression.
- To provide a method for multiplexed enhancer targeting.
Methods Used
- Designing guide RNAs using E-CRISP for low off-target effects.
- Using UCSC genome browser for alignment and localization of guide RNAs.
- Performing Gibson Assembly for constructing plasmids.
- Transfecting cells with plasmids containing guide RNAs.
Main Results
- Successful identification of enhancer regions involved in gene regulation.
- Demonstrated the ability to multiplex enhancer targeting.
- Provided a streamlined protocol for guide RNA design and assembly.
- Facilitated further studies on enhancer-gene interactions.
Conclusions
- This protocol enables efficient enhancer targeting for gene regulation studies.
- It enhances understanding of complex gene regulatory networks.
- Future applications may include therapeutic interventions targeting enhancers.
Frequently Asked Questions
What is the main advantage of this protocol?
The main advantage is the ability to test multiple enhancers simultaneously, allowing rapid identification of regulatory regions.
How are guide RNAs designed?
Guide RNAs are designed using E-CRISP to ensure low off-target effects and specificity for the target regions.
What is the role of the UCSC genome browser in this protocol?
The UCSC genome browser is used to align and visualize guide RNA sequences within the genome to assess their uniqueness.
What is Gibson Assembly?
Gibson Assembly is a method used to join DNA fragments together in a single, isothermal reaction.
What cell types can be used for transfection?
The protocol can be adapted for various cell types, including Ishikawa cells as mentioned in the study.
How does this protocol contribute to gene regulation research?
It provides a systematic approach to dissect enhancer functions and their interactions with target genes.
Executive Industry Relevance
Understanding enhancer function is critical for target validation in drug discovery, as enhancers modulate disease-relevant gene expression. The Enhancer-i method enables rapid, multiplexed interrogation of regulatory elements, supporting mechanistic de-risking and predictive confidence in early discovery. This approach helps prioritize targets by clarifying which enhancers drive transcriptional responses in disease contexts.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates enhancer contributions to gene expression, clarifying therapeutic hypothesis validity.
- Operational Value: Enables simultaneous testing of multiple enhancers, accelerating target de-risking.
- Predictive Value: Determines enhancer necessity and combinatorial effects, improving target confidence.
Screening & Assay Development
- Scientific Value: Generates quantitative readouts of enhancer activity via transcriptional response measurement.
- Operational Value: Uses transient transfection for scalable, reproducible enhancer screening in cell lines.
- Assay Readiness: Produces standardized biological systems for downstream compound evaluation.
Translational & Preclinical Research
- Translational Continuity: Links enhancer function to disease-relevant gene regulation in human cell models.
- Mechanistic De-risking: Identifies non-contributing enhancers, reducing ambiguity in target modulation strategies.
- Preclinical Alignment: Supports biomarker-ready models by defining functional regulatory elements.
Pipeline & Workflow Integration
The method fits within early discovery to lead identification, enabling enhancer validation before assay development and screening campaigns.
- Discovery Biology: Supports hypothesis testing of enhancer-gene relationships and pathway clarification.
- Screening: Delivers assay-ready systems with quantifiable transcriptional outputs for compound testing.
- Analytics: Provides enhancer activity measurements that inform dose-response and target engagement studies.
- Translational Research: Connects enhancer modulation to phenotypic outcomes in disease-relevant models.
- Enterprise Reuse: Establishes a reusable platform for enhancer screening across multiple targets and projects.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by defining enhancer necessity and combinatorial logic.
- Operational Value: Offers standardized, transient enhancer modulation compatible with high-throughput workflows.
- Strategic Value: Improves go/no-go decisions by reducing mechanistic ambiguity in target validation.
- Portfolio Impact: Enables risk-adjusted target prioritization based on enhancer-driven expression profiles.
Implementation Considerations
- Requires expertise in guide RNA design and CRISPR-based modulation techniques.
- Dependent on transfection efficiency and access to molecular cloning infrastructure (e.g., Gibson Assembly).
- Needs cross-team standardization for guide RNA validation and off-target assessment.
- Adaptable to various cell lines, though optimization may be needed for primary or hard-to-transfect systems.
- Limited to transcriptional readouts; requires integration with orthogonal assays for functional validation.
Biopharma FAQs
Why does enhancer necessity testing matter for target validation?
Determining whether an enhancer is necessary for gene expression helps validate targets by clarifying which regulatory elements drive disease-relevant transcription. This reduces false positives in target selection by focusing on enhancers with measurable impact on transcriptional output. Such insights improve predictive confidence in early-stage target hypotheses.
How does isolating individual enhancer contributions fit the discovery pipeline?
Isolating enhancer contributions allows researchers to deconvolute complex regulatory landscapes and assign functional weight to specific elements. This supports hypothesis-driven target validation by identifying key drivers of gene expression. The method fits early discovery by enabling rapid, multiplexed assessment before committing to lead identification.
What quantitative transcriptional measurements enable enhancer assessment?
The protocol measures changes in gene expression following enhancer interference, providing a quantitative readout of enhancer activity. These measurements allow comparison of individual and combinatorial enhancer effects on transcriptional response. Such data supports dose-response modeling and target engagement predictions in downstream assays.
Why do replication requirements matter for cross-functional collaboration?
Replication ensures that enhancer activity measurements are consistent across experiments, enabling reliable data sharing between discovery, assay development, and preclinical teams. Consistent results build confidence in target validation outcomes and support standardized decision-making. This reproducibility is essential for aligning cross-functional efforts on target prioritization.
What statistical analysis capabilities are required before implementing enhancer interference studies?
Implementing Enhancer-i requires statistical frameworks to compare transcriptional changes across conditions, including controls and combinatorial guide RNA sets. Analysis must account for variability in transfection efficiency and biological replicates to detect significant expression changes. These capabilities ensure that enhancer contributions are interpreted with appropriate confidence thresholds.
